DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicants’ election without traverse of Group I (i.e., claims 1-2, 5, 7, 10, 12, 14, 19 and 21) in the reply filed on 09/09/2026 is acknowledged.
Applicants’ amendment of claims 2, 5, 7, 10, 12, 14, 19 and 21 is acknowledged.
Furthermore, applicant’s election of the following species “Compound 19” for Group I
PNG
media_image1.png
172
200
media_image1.png
Greyscale
without traverse is acknowledged.
Since the applicant elected group I (i.e., claims 1-2, 5, 7, 10, 12, 14, 19 and 21), therefore, based on that election, claims 22-23, 26, 28, 31, 33, 35, 40, 46-47 and 65 are withdrawn as being drawn to a non-elected group.
Claims 1-2, 5, 7, 10, 12, 14, 19, and 21 are under consideration in this office action and will be examined on the merits.
Status of Claims
Claims 1-66 were originally pending. The preliminary amendment filed 09/09/2024
amended claims 2, 5, 7, 10, 12, 14, 19, 21, 23, 26, 28, 31, 33, 35, 40, 46-47, and 65; canceled
claims 3-4, 6, 8-9, 11, 13, 15-18, 20, 24-25, 27, 29-30, 32, 34, 36-39, 41-45, 48-64, and 66. There are no new claims.
Claims 1-2, 5, 7, 10, 12, 14, 19 and 21 are under consideration in the instant office action.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 09/09/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-2, 5, 7, 10, 12, 14, 19, and 21 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by US PG-PUB 2014/0248646 A1 to Hutt et al. (“IMIDAZO1.5-APYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME”, published September 4, 2014) herein referred to as Hutt.
Regarding claims 1-2, 5, 7, 10, 12, 14, 19 and 21, Hutt teaches Imidazo[1,5-a] pyridinium ion core having the formula similar to the compounds of Formula I.
PNG
media_image2.png
78
658
media_image2.png
Greyscale
PNG
media_image3.png
234
470
media_image3.png
Greyscale
Hutt discloses a compound comprising azo[1.5-a]pyridinium core of formula I (Compound 21, or 5-(4-(dimethylamino)phenyl)-2-(4-methoxyphenyl)-2H-imidazo[1.5-ajpyridin-4-ur tetraphenylborate, as shown in schemes 3 and 4 on page 26 of the instant application, the compound of the formula I shown as the compound 3-1 in schemes 3 and 4, can exist in two tautomeric forms having positive charge either at the N2 nitrogen atom or N4 nitrogen atom of the imidazo[1.5-a]pyridinium core, the numbering of the core is in accordance with the system shown in paragraph [0206]; paragraphs [0204], [0206]), wherein
T1 is CR1a, R1a is H (the hydrogen is attached to the C6 carbon atom of the imidazo[1.5-a]pyridinium core, the numbering of the core is in accordance with the system shown in paragraph [0206]; paragraphs [0204], [0206]);
T2 is CR2a, R2a is H (the hydrogen is attached to the C7 carbon atom of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]);
T3 is CR3a, R3a is H (the hydrogen is attached to the C8 carbon atom of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]);
R2 is H (the hydrogen is attached to the c1 carbon atom of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]);
R3 is substituted C6 aryl, wherein substituent in R3 is C1 alkoxy (4-methoxyphenyl moiety is attached to the N2 nitrogen of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]);
R4 is phenyl substituted with N(RA)(RB), RA and RB are H (the 4-(dimethylamino)phenyl moiety is attached to the C5 carbon of the imidazo[1.5-a]pyridinium core; paragraphs [0204], [0206]);
X is a counter anion (the tetraphenylborate counter ion as in the compound; paragraphs [0204], [0206]); wherein if T1 is CH, T2 is CH, T3, is CH, and R2 is H, then each of the following apply:
If R4 is 2,4,6-triisopropylphenyl, then R3 is not 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl, 2-methylphenyl, or 2,6-diethyl-4-methylphenyl (R4 is 4-(dimethylamino)phenyl, not 2,4,6-trilsopropylphenyl; paragraphs [0204], [0206]);
b) If R4 is 2,4,6-trimethylphenyl, then R3 is not 2,4,6-trimethylphenyl, 2,6-diisopropylphenyl, adamantly, 4-(2-(2-methoxyethoxy)ethoxy)-2,6-dimethylphenyi, or (2-(2-methoxyethoxy)ethoxy)phenyl (R4 is 4-(dimethylamino)phenyl, not 2,4,6-trimethylphenyl; paragraphs [0204], [0206]);
c) If R4 is 2-methylphenyl, then R3 is not 2,6-diisopropylphenyl (R4 is 4-(dimethylamino)phenyl, not 2-methylphenyl; paragraphs [0204], [0206]);
d) If R4 is 4-tert-butyl-2-pyridyl, then R3 is not 2,6-diisopropylphenyl (R4 is 4-(dimethylamino)phenyl, not paragraphs [0204], [0206]); and
e) If R4 is 5-tetrahydroisoquinolinyl, then R3 is not 2,6-dilsopropylphenyl (R4 is 4-(dimethylamino)phenyl, not 5-tetrahydroisoquinolinyl; paragraphs [0204], [0206]).
The scope of Hutt’s compounds overlaps with Formula I of the instant claims. Based on the foregoing reasons, the instant claims are deemed anticipated over the cited art.
Conclusion
Claims 1-2, 5, 7, 10, 12, 14, 19 and 21 are rejected. No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAHAR INAM whose telephone number is (571)272-0821. The examiner can normally be reached 7:30 am-5:00 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SAHAR INAM/
Examiner, Art Unit 1622
/JAMES H ALSTRUM-ACEVEDO/
Supervisory Patent Examiner, Art Unit 1622